Financial Performance - Mirion's Q1 2025 revenue reached $202 million, reflecting a 49% total increase and a 60% organic growth compared to Q1 2024[10, 19] - Adjusted EBITDA for Q1 2025 was $467 million, an 182% increase from Q1 2024, with a margin expansion of 260 bps[9, 10] - Adjusted EPS increased by 667% to $010 in Q1 2025 from $006 in Q1 2024[22] - Adjusted Free Cash Flow for Q1 2025 was $29 million, a significant improvement compared to previous years[9, 39] Orders and Backlog - Strong Q1 orders with an 115% increase compared to Q1 2024, indicating consistent demand[9, 10] - The company repurchased 116 million shares in Q1 2025 as part of its capital deployment strategy[11] - Backlog trend shows a slight decrease of 1% vs adjusted Q1 2024, reaching $814 million in Q1 2025[48] Segment Performance - Nuclear & Safety segment revenue grew by 60% in Q1 2025, with organic growth of 76%[25] - Medical segment revenue increased by 27% in Q1 2025, with organic growth of 30%[32] Guidance and Outlook - The company reaffirms its 2025 guidance for Organic Revenue Growth (55% - 75%), Adjusted EBITDA ($215 - $230 million), Adjusted FCF, and Adjusted EPS[41]